What is the time commitment for patients participating in ATTRACT-2?
A treatment cycle is 21 days. Study treatment with docetaxel will be administered for a maximum of six cycles. Once these six cycles have been completed, patients may continue to receive ASA404 or placebo as maintenance treatment for NSCLC until disease progression, unacceptable toxicity, or withdrawal of consent. Patients will be followed every six weeks (two cycles) for survival following treatment completion, discontinuation or documented disease progression until either death or the data cutoff date.
